Based on the review, the researchers promote the integration of GLP-1 receptor agonists as a primary treatment for obesity in ...

Coya Therapeutics (COYA) releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan….”Given my recent ...

Glucagon-like peptide-1 receptor agonists are FDA-approved medications that mimic the action of a naturally occurring hormone ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

which is the Company’s first generic injectable glucagon-like peptide-1 (GLP-1) agonist and reflects its innovation capabilities in peptide development and drug-device combinations. Resubmission ...

On November 18, at the American Heart Association (AHA) 100th Annual Meeting 2024, the safety of glucagon-like peptide-1 receptor (GLP-1R) agonists ... any action on the basis of the content ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a lower risk for venous thromboembolism (VTE).

Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the ...

It stands to reason, then, that if there are similar mechanisms that drive us to overeat and take drugs, and a GLP-1 agonist works on the one for overeating, then a GLP-1 agonist could also ...

Cambridge UK biopharma company Apollo Therapeutics could pay around $1 billion to Chinese company Sunshine Lake Pharma to ...